Q-omics provides the consensus-scored IL4 profile across patient tissues and cancer cell-line models. IL4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IL4 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, IL4 RNA expression shows 13,607 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where IL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL4 survival associations across molecular data types. IL4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL4 RNA expression–survival associations across cancer types. High IL4 expression shows unfavorable associations in KIRC, ACC, MESO and LUSC, but favorable associations in BRCA and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IL4 RNA expression.
This table summarizes IL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL4 shows lower tumor expression in LUSC, BRCA and UCEC and higher tumor expression in THCA, ESCA and CHOL. The LUSC box plot shows higher IL4 RNA expression in normal versus tumor tissue (log2 FC = −0.200, t-test p < 0.001).
This table shows molecular features associated with IL4 in patient tissues and cancer cell lines. In patient samples, IL4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
